Novel Compounds Inhibiting COVID-19 Replication

Case ID:

This technology is three potential pharmacological treatment options for COVID-19. The inventors identified three compounds, two naturally occurring and one small-molecule. These compounds target and inhibit the main 3CL protease that is essential to the replication of SARS-CoV-2 and have been shown to be effective against the virus in vitro.

In March of 2020, SARS-CoV-2, a novel coronavirus, became a global pandemic and since then has infected more than 92 million people worldwide, killing nearly 2 million of those people. Even over a year since the first SARS-CoV-2 was reported, there are still very few treatment options available to counteract the negative effects of the viral infection. Although COVID-19 vaccinations are beginning to be widely distributed, the U.S. is still far from reaching herd immunity and many countries around the world still do not have access to the vaccine. In fact, in countries like India, where vaccine supply is low, there have been recent surges in COVID-19 cases and deaths. Therefore, it is imperative to develop effective treatments for SARS-CoV-2.

This technology provides three potential pharmacological treatment options for COVID-19 that have been demonstrated as effective to inhibit SARS-CoV-2 replication, making this treatment a potential method to stop the spread of COVID-19 and end the global pandemic that has now stretched over one year.


  • Treatment for SARS-CoV-2
  • 3CLPro inhibition


  • Novel clinical treatment
  • Non-invasive treatment option
  • Non-vaccine treatment for areas that lack vaccine supply
  • Potential to end global pandemic
Patent Information:
Contact For More Information:
Mitch Graffeo
Sr. Licensing Manager - COM-T
The University of Arizona
Lead Inventor(s):
Rui Chang
Dominik Schenten
Patrick Ronaldson
Yanyun Liu
Vijayan Ramachandran